In ongoing clinical trial research (NCT03710421), SLAMF7-CAR T-cells have been engineered by incorporating an anti-SLAMF7 single-chain variable fragment (ScFv), memory-enriched T cells, and a truncated EGFR (EGFRt) molecule to target multiple myeloma cells [82]. This evidence concerns the gene SLAMF7 and AL amyloidosis.